Company intelligence / Profile preview
Urigen Pharmaceuticals, Inc.
North Brunswick, New Jersey, United Statesurigen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
URG101 demonstrated safety and efficacy for reducing symptoms of pelvic pain and urgency in double-blind placebo-controlled Phase II studies. Some clinical programs appear to be terminated or dormant as of the latest available data.[10]
- Therapeutic areas
- Men's HealthNephrologyWomen's Health
- Modalities
- Small moleculesCombination products of approved drugs
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
None recently disclosed; historical technology transfer agreements with Vical Incorporated and Genetronics Biomedical Corporation during merger period with Valentis.[9]
Beyond the preview
Go deeper on Urigen Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Urigen Pharmaceuticals, Inc..